Lumizyme market seen expanding on rare disease demand

The Business Research Company says the global Lumizyme market should keep growing through 2035, driven by more rare disease diagnoses, rising healthcare spending and wider use of home infusion care. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - Lumizyme is a key enzyme replacement therapy for Pompe disease, a rare inherited disorder with serious long-term health effects. - The market outlook points to sustained demand as diagnosis, treatment access and rare disease awareness improve worldwide. - Growth in this niche market also signals broader investment in rare disease therapies and specialty care infrastructure.

What happened: - The Business Research Company released its Lumizyme Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says the Lumizyme market has been shaped by medical advances, growing awareness of rare genetic conditions and improved specialty care. - North America held the largest share of the market in 2025. - Asia-Pacific is forecast to post the fastest growth during the outlook period.

The details: - Lumizyme is the brand name for alglucosidase alfa. - Lumizyme treats Pompe disease by replacing the enzyme acid alpha-glucosidase, or GAA. - Pompe disease causes glycogen buildup in cells when the body lacks enough GAA. - Historical growth was tied to greater awareness of lysosomal storage disorders, recombinant enzyme manufacturing progress, early regulatory clearances for enzyme replacement therapies, specialty care centers and rare disease registries. - Forecast growth is supported by investment in rare disease therapies, wider acceptance of home-based infusion, newborn screening programs, stronger demand for improved enzyme formulations and continued innovation in enzyme replacement technology. - The report highlights increased use of enzyme replacement therapy for rare diseases, earlier Pompe diagnosis, lifelong treatment plans, growth in home infusion services and stronger patient support programs. - The report cites rising prevalence of rare genetic disorders as a major driver. - In March 2023, National Library of Medicine data estimated Pompe disease incidence at about 1 in 40,000 people. - The report also points to rising global healthcare spending as a growth factor. - UK Office for National Statistics data showed healthcare expenditure grew 5.6% from 2022 to 2023, versus 0.9% in 2022. - The market analysis spans Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample is available here. - The full report is available here.

Between the lines: - The forecast suggests the market’s biggest gains may come from earlier detection and broader treatment access, not just from new drug development. - Home infusion growth and newborn screening expansion could make treatment more routine for patients and less dependent on large specialty centers. - North America’s lead likely reflects earlier adoption of advanced therapies, while Asia-Pacific’s outlook points to expanding access and infrastructure rather than an already mature market.

What's next: - The report expects rare disease investment, diagnostic expansion and home-based care models to keep supporting demand through 2035. - The company’s 2026 report package adds TAM analysis, company scoring matrices, forecasting dashboards, hotspot infographics and updated graphics and tables. - The Business Research Company is also promoting expert contact options for buyers seeking the full market analysis.

The bottom line: - Lumizyme’s market is positioned for long-term growth as rare disease screening and treatment access broaden, with the strongest near-term momentum expected outside North America.